BR112014020233A2 - seleção de paciente com câncer para administração de inibidores sinalizantes wnt usando status de mutação rnf43 - Google Patents

seleção de paciente com câncer para administração de inibidores sinalizantes wnt usando status de mutação rnf43

Info

Publication number
BR112014020233A2
BR112014020233A2 BR112014020233A BR112014020233A BR112014020233A2 BR 112014020233 A2 BR112014020233 A2 BR 112014020233A2 BR 112014020233 A BR112014020233 A BR 112014020233A BR 112014020233 A BR112014020233 A BR 112014020233A BR 112014020233 A2 BR112014020233 A2 BR 112014020233A2
Authority
BR
Brazil
Prior art keywords
rnf43
administration
znrf3
cancer patient
wnt signaling
Prior art date
Application number
BR112014020233A
Other languages
English (en)
Inventor
Cong Feng
Hsieh Hsin-I
Hao Huaixiang
Liu Jun
Ng Nicholas
Jiang Xiaomo
Original Assignee
Irm Llc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47790546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014020233(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc, Novartis Ag filed Critical Irm Llc
Publication of BR112014020233A2 publication Critical patent/BR112014020233A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo patente de invenção: "seleção de paciente com câncer para administração de inibidores sinalizantes wnt usando status de mutação rnf43". são mostrados biomarcadores, processos e ensaio para a identificação de pacientes de câncer que são previstos beneficiarem-se da administração terapêutica de antagonista de wnt. os biomarcadores incluem detecção de supressão de gene rnf43 e znrf3, reduzida expressão de mrna de rnf43 e znrf3, reduzida expressão de proteína rnf43 e znrf3, mutação de inativação de rnf43 e znrf3, lrp6 fosforilada, dishevelleds fosforiladas, e a expressão de frizzleds. estes biomarcadores podem ser associados com o melhor resultado para pacientes de câncer tratados com inibidores de caminho wnt. 22067300v1 1/1 22067300v1
BR112014020233A 2012-02-28 2013-02-22 seleção de paciente com câncer para administração de inibidores sinalizantes wnt usando status de mutação rnf43 BR112014020233A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261604290P 2012-02-28 2012-02-28
PCT/US2013/027441 WO2013130364A1 (en) 2012-02-28 2013-02-22 Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status

Publications (1)

Publication Number Publication Date
BR112014020233A2 true BR112014020233A2 (pt) 2017-07-04

Family

ID=47790546

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014020233A BR112014020233A2 (pt) 2012-02-28 2013-02-22 seleção de paciente com câncer para administração de inibidores sinalizantes wnt usando status de mutação rnf43

Country Status (20)

Country Link
US (3) US20150125857A1 (pt)
EP (2) EP2820151B1 (pt)
JP (2) JP6397335B2 (pt)
KR (1) KR20140132712A (pt)
CN (1) CN104302782A (pt)
AU (1) AU2013226323B2 (pt)
BR (1) BR112014020233A2 (pt)
CA (1) CA2864306A1 (pt)
CL (1) CL2014002269A1 (pt)
ES (2) ES2968742T3 (pt)
HK (1) HK1199744A1 (pt)
IL (1) IL233920A0 (pt)
MX (1) MX2014010265A (pt)
NZ (1) NZ627864A (pt)
PH (1) PH12014501930A1 (pt)
RU (2) RU2636000C2 (pt)
SG (1) SG11201404492VA (pt)
TN (1) TN2014000337A1 (pt)
WO (1) WO2013130364A1 (pt)
ZA (1) ZA201405553B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012271413B2 (en) 2011-06-17 2017-07-13 President And Fellows Of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
EP3653222A1 (en) 2011-10-14 2020-05-20 Novartis AG Antibodies and methods for wnt pathway-related diseases
CN104302782A (zh) 2012-02-28 2015-01-21 诺华股份有限公司 利用rnf43突变状态选择wnt信号转导抑制剂给药的癌症患者
JP2016518328A (ja) 2013-03-12 2016-06-23 キュアジェニックス インコーポレイテッド 癌治療のための化合物
WO2015145388A2 (en) * 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
SG11201608715WA (en) * 2014-04-21 2016-11-29 Abbvie Stemcentrx Llc Novel antii-rnf43 antibodies and methods of use
EP3204378B3 (en) * 2014-10-08 2022-05-25 Redx Pharma PLC N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway
US20160312207A1 (en) * 2015-04-21 2016-10-27 The Board Of Trustees Of The Leland Stanford Junior University R-spondin antagonists and methods of treating cancer associated with aberrant activation of wnt signaling
CA2985813A1 (en) * 2015-05-26 2016-12-01 Curegenix Corporation Tumor biomarkers and use thereof
CN110234662A (zh) 2017-01-26 2019-09-13 瑟罗泽恩公司 组织特异性wnt信号增强分子和其用途
WO2019245460A1 (en) * 2018-06-21 2019-12-26 National University Of Singapore Stratifying cancer patients harbouring oncogenic mutations in the e3 ubiquitin ligase rnf43
US20210299233A1 (en) * 2018-07-12 2021-09-30 The Children's Medical Center Corporation Method for treating cancer
EP3986912A1 (en) 2019-06-21 2022-04-27 Regeneron Pharmaceuticals, Inc. Treatment of decreased bone mineral density with zinc and ring finger 3 (znrf3) inhibitors
CN113564249B (zh) * 2020-04-28 2023-06-16 中国科学院分子细胞科学卓越创新中心 CXorf67在判断肿瘤对DNA损伤药物的敏感性中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148408A1 (en) 2001-09-18 2003-08-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
DK1513934T3 (da) * 2002-06-06 2011-05-02 Oncotherapy Science Inc Gener og polypeptider relateret til humane coloncancersygdomme
ES2361541T3 (es) * 2002-06-06 2011-06-17 Oncotherapy Science, Inc. Genes y polipéptidos relacionados con cánceres de colon humanos.
CA2501235A1 (en) * 2002-10-04 2004-04-22 The Regents Of The University Of California Methods for treating cancer by inhibiting wnt signaling
WO2004086949A2 (en) 2003-03-25 2004-10-14 John Wayne Cancer Institute Dna markers for management of cancer
CN101687005A (zh) * 2004-07-09 2010-03-31 加利福尼亚大学董事会 采用抑制Wnt 16信号转导的试剂治疗癌症的方法
JP2008519829A (ja) * 2004-11-10 2008-06-12 ヒュブレヒト ラボラトリウム Ｎｏｔｃｈ経路活性化の阻害による腸腺腫および／または腺癌の処置
WO2006101925A2 (en) 2005-03-16 2006-09-28 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
WO2011004379A1 (en) * 2009-07-10 2011-01-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions and methods for treating cancer
EP2549399A1 (en) 2011-07-19 2013-01-23 Koninklijke Philips Electronics N.V. Assessment of Wnt pathway activity using probabilistic modeling of target gene expression
EP3653222A1 (en) 2011-10-14 2020-05-20 Novartis AG Antibodies and methods for wnt pathway-related diseases
CN104302782A (zh) 2012-02-28 2015-01-21 诺华股份有限公司 利用rnf43突变状态选择wnt信号转导抑制剂给药的癌症患者
LT3383425T (lt) 2015-12-04 2020-10-12 Boehringer Ingelheim International Gmbh Biparatopiniai polipeptidai, veikiantys antagonistiškai wnt signaliniam keliui vėžinėse ląstelėse

Also Published As

Publication number Publication date
EP3693476A1 (en) 2020-08-12
RU2017120287A (ru) 2018-11-15
ES2797533T3 (es) 2020-12-02
HK1199744A1 (en) 2015-07-17
JP6397335B2 (ja) 2018-09-26
KR20140132712A (ko) 2014-11-18
RU2014139044A (ru) 2016-04-20
EP2820151B1 (en) 2020-03-25
AU2013226323A1 (en) 2014-09-11
CL2014002269A1 (es) 2014-12-19
WO2013130364A1 (en) 2013-09-06
JP2018172408A (ja) 2018-11-08
US20190203301A1 (en) 2019-07-04
TN2014000337A1 (en) 2015-12-21
CN104302782A (zh) 2015-01-21
RU2636000C2 (ru) 2017-11-17
PH12014501930A1 (en) 2014-11-24
AU2013226323B2 (en) 2016-07-14
MX2014010265A (es) 2015-06-23
CA2864306A1 (en) 2013-09-06
EP2820151A1 (en) 2015-01-07
SG11201404492VA (en) 2014-10-30
JP2015511484A (ja) 2015-04-20
EP3693476B1 (en) 2023-10-18
US20170306409A1 (en) 2017-10-26
IL233920A0 (en) 2014-09-30
ES2968742T3 (es) 2024-05-13
NZ627864A (en) 2015-12-24
ZA201405553B (en) 2015-12-23
US20150125857A1 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
BR112014020233A2 (pt) seleção de paciente com câncer para administração de inibidores sinalizantes wnt usando status de mutação rnf43
AU2018256477A1 (en) Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
BR112013027774A2 (pt) novos compostos como moduladores de proteína quinases
BR112015009624A2 (pt) inibidores de tirosina cinase de bruton
BR112016029041A2 (pt) terapia de combinação com inibidores de glutaminase
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
BR112014031088A2 (pt) métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal
BR112015012536A2 (pt) tratamento de câncer com inibidores heterocíclicos da glutaminase
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
EA201201508A1 (ru) Комбинированная терапия
EA201500334A1 (ru) Fgfr3 гибридный ген и лекарственный препарат, нацеленный на него
BR112017010788A2 (pt) métodos de identificação de um paciente com câncer e de identificação de um paciente que sofre de câncer que pode beneficiar da administração de um antagonista de vegf, método de tratamento de um paciente com câncer e método para determinar o estágio de câncer de ovário
AR080643A1 (es) Identificacion de la mutacion de lkb1 como un biomarcador predictivo para la sensibilidad a inhibidores de la tor quinasa
CO6551721A2 (es) Moduladores de cinasa novedosos
BR112014011127A2 (pt) métodos para tratar, diagnosticar e monitorar doença de alzheimer
BR112014004465A2 (pt) compostos e composições como inibidores de pdgfr cinase
BR112012022943A2 (pt) inibidores de syk de imidazopiridnas
IN2014CN03465A (pt)
CO7151491A2 (es) Método para la identificación del origen de un cancer de origen primario desconocido
BR112014026057A2 (pt) análogos limitados por anel como inibidores de arginase
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
MX2014014097A (es) Biomarcadores para determinar la respuesta eficaz de tratamientos en pacientes de carcinoma hepatocelular (chc).
BR112016028446A2 (pt) inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5
BR112015010220A2 (pt) métodos de utilização de biomarcadores para tratamento de câncer
MX2021000133A (es) Uso de compuestos conocidos como inhibidores de la d-aminoacido oxidasa.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2554 DE 17/12/2019.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]